含有坎佛的异环化合物的半合成和生物活性
Zeinab S Hamza1, Wael N Hozzein2, Khaled El-Adl3,4
1Chemistry of Medicinal and Aromatic Plants Department, Research Institute of Medicinal and Aromatic Plants (RIMAB), Beni-Suef University Beni-Suef 62511 Egypt h_gendy_2010@yahoo.com Husseinshaban@rimp.bsu.edu.eg +201000800296.
新型花衍生化合物对乳腺癌和肺癌细胞系表现出强烈的抗癌活性. 与标准药物相比,化合物20显示出更高的疗效,突出显示了它作为一种新的癌症治疗药物的潜力.
科学领域:
- 药用化学 医学化学
- 有机合成 有机合成
- 癌症研究 癌症研究
背景情况:
- 乳腺癌和肺癌是全球癌症相关死亡的主要原因.
- 现有治疗方法面临挑战,需要开发新型治疗剂.
- 自然产品为发现新的抗癌化合物提供了丰富的来源.
研究的目的:
- 合成来自的新型异环化合物.
- 评估这些化合物对癌症细胞系的体外细胞毒性.
- 为了确定乳腺和肺癌治疗的强效抗癌药物.
主要方法:
- 坎佛衍生异环化合物的化学合成.
- 使用MCF-7 (乳腺) 和A549 (肺) 癌细胞系进行细胞毒性测定.
- 确定半最大抑制度 (IC50) 的值.
- 分子对接研究,以预测结合相互作用.
主要成果:
- 化合物20对MCF-7细胞表现出显著的细胞毒性 (IC50 = 0.78μM),表现优于达沙替尼和多克索鲁比辛.
- 化合物20也对A549细胞表现出强烈的活性 (IC50 = 1.69 μM),超过标准药物的活性.
- 分子对接表明,化合物20具有最高的结合能,支持其观察到的有效性.
结论:
- 合成的坎佛衍生异环,特别是化合物20,显示出有前途的抗癌潜力.
- 化合物20是作为治疗乳腺癌和肺癌的治疗剂进一步开发的强有力的候选者.
- 这些发现有助于寻找有效和新的癌症治疗方法.
更多相关视频
07:30A Direct, Regioselective and Atom-Economical Synthesis of 3-Aroyl-N-hydroxy-5-nitroindoles by Cycloaddition of 4-Nitronitrosobenzene with Alkynones
Published on: January 21, 2020
11:04Preparation of Enantiopure Non-Activated Aziridines and Synthesis of Biemamide B, D, and epiallo-Isomuscarine
Published on: June 13, 2022
相关概念视频
Aromatic Compounds: Overview
In 1825, Faraday...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Five-Membered Heterocyclic Aromatic Compounds: Overview
Criteria for Aromaticity and the Hückel 4n + 2 Rule
For the first time, Eric Hückel, a German chemical physicist, derived a set of structural features for a compound to be classified as aromatic. This is now known as...
Organic Compounds
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...
